Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity
Identifieur interne : 000611 ( Istex/Curation ); précédent : 000610; suivant : 000612Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity
Auteurs : J. M. Van Kampen [Canada] ; E. G. Mcgeer [Canada] ; A. Jon Stoessl [Canada]Source :
- Synapse [ 0887-4476 ] ; 2000-09-01.
English descriptors
- KwdEn :
Abstract
The plasma membrane dopamine transporter is located on presynaptic nerve terminals and is responsible for the termination of dopaminergic neurotransmission via dopamine reuptake. The dopamine transporter may also contribute to the pathogenesis of Parkinson disease. Dopamine transporter expression correlates well with susceptibility to neuronal degeneration in 1‐methyl‐4‐phenyl‐1,2,3,6 ‐tetrahydropyridine (MPTP)‐induced parkinsonism. Recent studies have implicated the dopamine transporter in the uptake of both this neurotoxin and its metabolite, MPP+, as well as another experimental neurotoxin, 6‐hydroxydopamine. In these studies we examined the role of the dopamine transporter in the neurotoxicity of both MPP+ and 6‐hydroxydopamine in the rat brain using in vivo administration of phosphorothioate antisense oligonucleotides targeting dopamine transporter mRNA. Infusion of dopamine transporter antisense (1 nmol/day, 7 days) into the left substantia nigra pars compacta resulted in reduced 3H‐WIN 35‐428 binding in the left striatum and significant levodopa and amphetamine‐induced contralateral rotations. Unilateral pretreatment with dopamine transporter antisense prior to bilateral intrastriatal infusion of either MPP+ or 6‐hydroxydopamine resulted in asymmetrical striatal 3H‐WIN 35‐428 binding and dopamine content as well as significant apomorphine‐induced ipsilateral rotations, suggesting neuroprotection of nigrostriatal neurons on the antisense‐treated side. Thus, the dopamine transporter appears to play a critical role in determining susceptibility to the experimental neurotoxins MPP+ and 6‐hydroxydopamine. In light of this, the dopamine transporter may prove useful, both as a marker for susceptibility to Parkinson's disease and as a target for therapeutic intervention. Synapse 37:171–178, 2000. © 2000 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/1098-2396(20000901)37:3<171::AID-SYN1>3.0.CO;2-R
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000611
Links to Exploration step
ISTEX:E2DF7878F5224D9B5095653D71FCD06986FB0900Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity</title><author><name sortKey="Van Kampen, J M" sort="Van Kampen, J M" uniqKey="Van Kampen J" first="J. M." last="Van Kampen">J. M. Van Kampen</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C.</wicri:regionArea></affiliation></author><author><name sortKey="Mcgeer, E G" sort="Mcgeer, E G" uniqKey="Mcgeer E" first="E. G." last="Mcgeer">E. G. Mcgeer</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C.</wicri:regionArea></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C.</wicri:regionArea></affiliation><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, 2221 Wesbrook Mall Rm M36, Vancouver, British Columbia, Canada, V6T 2B5</mods:affiliation><wicri:noCountry code="subField">2B5</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E2DF7878F5224D9B5095653D71FCD06986FB0900</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1098-2396(20000901)37:3<171::AID-SYN1>3.0.CO;2-R</idno><idno type="url">https://api-v5.istex.fr/document/E2DF7878F5224D9B5095653D71FCD06986FB0900/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000611</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000611</idno><idno type="wicri:Area/Istex/Curation">000611</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity</title><author><name sortKey="Van Kampen, J M" sort="Van Kampen, J M" uniqKey="Van Kampen J" first="J. M." last="Van Kampen">J. M. Van Kampen</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C.</wicri:regionArea></affiliation></author><author><name sortKey="Mcgeer, E G" sort="Mcgeer, E G" uniqKey="Mcgeer E" first="E. G." last="Mcgeer">E. G. Mcgeer</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C.</wicri:regionArea></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation wicri:level="1"><mods:affiliation>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, Vancouver, B.C.</wicri:regionArea></affiliation><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, 2221 Wesbrook Mall Rm M36, Vancouver, British Columbia, Canada, V6T 2B5</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-09-01">2000-09-01</date><biblScope unit="volume">37</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="171">171</biblScope><biblScope unit="page" to="178">178</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">E2DF7878F5224D9B5095653D71FCD06986FB0900</idno><idno type="DOI">10.1002/1098-2396(20000901)37:3<171::AID-SYN1>3.0.CO;2-R</idno><idno type="ArticleID">SYN1</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐hydroxydopamine</term><term>MPP+</term><term>amphetamine</term><term>levodopa</term><term>neurotoxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The plasma membrane dopamine transporter is located on presynaptic nerve terminals and is responsible for the termination of dopaminergic neurotransmission via dopamine reuptake. The dopamine transporter may also contribute to the pathogenesis of Parkinson disease. Dopamine transporter expression correlates well with susceptibility to neuronal degeneration in 1‐methyl‐4‐phenyl‐1,2,3,6 ‐tetrahydropyridine (MPTP)‐induced parkinsonism. Recent studies have implicated the dopamine transporter in the uptake of both this neurotoxin and its metabolite, MPP+, as well as another experimental neurotoxin, 6‐hydroxydopamine. In these studies we examined the role of the dopamine transporter in the neurotoxicity of both MPP+ and 6‐hydroxydopamine in the rat brain using in vivo administration of phosphorothioate antisense oligonucleotides targeting dopamine transporter mRNA. Infusion of dopamine transporter antisense (1 nmol/day, 7 days) into the left substantia nigra pars compacta resulted in reduced 3H‐WIN 35‐428 binding in the left striatum and significant levodopa and amphetamine‐induced contralateral rotations. Unilateral pretreatment with dopamine transporter antisense prior to bilateral intrastriatal infusion of either MPP+ or 6‐hydroxydopamine resulted in asymmetrical striatal 3H‐WIN 35‐428 binding and dopamine content as well as significant apomorphine‐induced ipsilateral rotations, suggesting neuroprotection of nigrostriatal neurons on the antisense‐treated side. Thus, the dopamine transporter appears to play a critical role in determining susceptibility to the experimental neurotoxins MPP+ and 6‐hydroxydopamine. In light of this, the dopamine transporter may prove useful, both as a marker for susceptibility to Parkinson's disease and as a target for therapeutic intervention. Synapse 37:171–178, 2000. © 2000 Wiley‐Liss, Inc.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000611 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000611 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:E2DF7878F5224D9B5095653D71FCD06986FB0900
|texte= Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity
}}
| This area was generated with Dilib version V0.6.29. |  |